Previous Close | 0.1000 |
Open | 0.0600 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 12.50 |
Expire Date | 2024-05-17 |
Day's Range | 0.0600 - 0.1000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
OSAKA, Japan, May 09, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER, in a year of significant loss-of-exclusivity impact.
Comprehensive Analysis of Q1 2024 Earnings and Strategic Developments
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.